Search
for
Sort by
Research 241–270 of 1000+
- Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
- Cutaneous manifestations of COVID-19 and vaccines for its prevention: a review of the existing literature
- Prevalence and Clinical Spectrum of Dermatologic Conditions in Renal Transplant Recipients: A 10-Year Retrospective Cross-Sectional Study
- Efficacy and safety of tofacitinib in patients with alopecia areata
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- A cross sectional study on geriatric dermatosis in patients attending a tertiary care hospital
- Geriatric Dermatologic Therapy
- Epidemiology and burden of alopecia areata in Taiwan: a systematic review
- Comparative safety profiles of baricitinib and tofacitinib in the treatment of adult alopecia areata: a pharmacovigilance study based on the FAERS database
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Coexistence of alopecia areata and fixed drug eruption: An uncommon isotopic phenomenon?
- A Cross-Sectional Analysis of Psychological and Dermatologic Manifestations Post-February 6 Earthquakes in Dermatology Patients
- Longitudinal clinical course, treatment outcomes, and relapse patterns in alopecia areata: a prospective cohort study
- Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
- Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches
- Do Dermatoses Trigger Neurodegenerative Diseases? A Retrospective Observational Study
- Evidence for the off-label use of tofacitinib in alopecia areata
- Journal of Population Therapeutics and Clinical Pharmacology
- Erosive Pustular Dermatosis of the Scalp Following Hair Transplantation: A Rare Complication
- Farmácia Padrão da Légua, Custóias e nos Serviços Farmacêuticos da Klinicka Bolnica Dubrava, Croácia
- Novel trends of frequency, demographics and clinical presentation of skin disorders in only public hospital in south of Lahore: A Descriptive observational study over 1 year.
- Ritlecitinib in severe alopecia areata: a profile of its use
- Vitiligo: are microbes to blame?
- Pengenalan Tumbuhan Lokal Untuk Kosmetik Kepada Gen Z : Edukasi Formulasi Sediaan Pomade Estrak Daun Meniran ((Phyllanthus Niruri L ) Sebagai Perangsang Penumbuh Rambut
- State of the art of photobiomodulation in Dermatology
- CARACTERÍSTICAS CLÍNICAS E EPIDEMIOLÓGICAS DO EFLÚVIO TELÓGENO PÓS COVID-19
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- Part Three (Cure Most Diseases by Logical Nutrition Treatment): The Society Agent Simulating (SAS) & Usage of Oral and Dental Diseases to Predict Criminals Earlier
- Dermatolojik Problemler ve COVID-19